Sitryx
Generated by Meeveem AI
"Pioneers in immunometabolism developing therapies to resolve autoimmune and inflammatory disease"
Oxford
•11 - 50 Employees
•Biotechnology
About Sitryx
Sitryx pioneers immunometabolic therapies that target metabolic pathways within immune cells. By modulating immune cell function at a cellular level, the company develops first and best in class oral therapies to rebalance the immune system and achieve sustained remission in chronic autoimmune and inflammatory conditions including atopic dermatitis, ulcerative colitis and allergic asthma. The approach corrects immune cell dysfunction rather than broadly suppressing immunity. With a pipeline of disease modifying therapeutics, collaborations with Eli Lilly and Boehringer Ingelheim, and backing from specialist investors, Sitryx translates breakthrough immunometabolism science into treatments for debilitating immune mediated diseases.
49
Team Members
2018
Founded
Biotechnology
Sector
On-Site
Work Environment
Our Vision
A world where chronic autoimmune and inflammatory diseases can be resolved through precision metabolic therapies that restore immune balance, enabling patients to achieve sustained remission and reclaim their quality of life.
Our Mission
Rebalances the immune system through disease modifying immunometabolic therapies that target intracellular metabolic pathways, achieving sustained remission in chronic autoimmune and inflammatory diseases.